Tenecteplase in STEMI
Other thromboly agents in STEMI
Tenecteplase in other conditions

This section contains overviews of the most important studies demonstrating the clinical benefits and conditions for appropriate use of thrombolytic therapy and percutaneous coronary intervention (PCI) for the treatment of ST-elevation myocardial infarction.

The growing number of thrombolytic studies has demonstrated that patients presenting with ST-elevation acute coronary syndromes clearly benefit from thrombolytic therapy. This chapter gives an overview of important studies concerning acute myocardial infarction and acute pulmonary embolism.

Some of these studies are already completed and the following chapter provides summaries of each of the studies, including trial design, results and conclusions. Other studies are still ongoing and so far only a limited amount of information is accessible. These subchapters will be updated as soon as more information becomes available.

We apply diligent efforts to provide the most accurate information. Notwithstanding this, we do not assume responsibility for any injury or damages to persons or property.

Due to the permanent advances in medical science, we strongly suggest you always consult the most current prescribing information for therapy, especially bearing in mind that these summaries are supposed to supply you with the latest news in practice and research, but may describe use of a drug eventually not backed by current regulatory approval.


*Tenecteplase (Metalyse®) is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left bundle branch block within 6 hours after the onset of acute myocardial infarction symptoms.

See prescribing Information for more details.